How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Targeting CYP11A1 in the Steroidogenic Pathway for Treating Allergic Diseases

Organization name

National Jewish Health

Profile

Background

CD4 Th2 and CD8 Tc2 cells play a pivotal role in the induction and control of allergic inflammation, including food allergy and asthma. In humans, allergen-specific Th2 CD4+ T cells are essential to the development and maintenance of both type I IgE-mediated and non-IgE-mediated food allergic responses. Steroid hormones, such as glucocorticoids (GCs), are part of a feedback mechanism that plays an important role in the regulation of the immune system. The anti-inflammatory activity of GCs is well described and this property is used to treat diseases caused by an overactive immune system, such as allergies, asthma, autoimmune diseases and sepsis. There is accumulating evidence suggesting that GCs can also promote the pathogenesis of allergic diseases by enhancing T-cell pro-allergic differentiation of CD4+T cells to Th2 and Th17, by amplifying immune responses in steroid-insensitive CD8+ T cells and by inhibiting Th1 cytokine production. Endogenous GC synthesis is regulated by the transcriptional control of steroidogenic enzymes of the cytochrome P450 gene family, such as CYP11A1.

Technology

Dr. Gelfand’s laboratory has identified CYP11A1, a member of the cytochrome P450 superfamily of enzymes that converts cholesterol to pregnenolone, as a key regulator of allergic responses through its effect on steroidogenesis. They demonstrated that CYP11A1 controls the phenotypic conversion of CD4+T cells to Th2 and Th17 and CD8+ T cells from INF-g to IL-13 producing cells, linking steroidogenesis to a pro-allergic differentiation pathway.Inhibition of CYP11A1 with aminoglutethimide in an animal model of peanut allergy prevented an allergic response and the accumulation of inflammatory cells in a dose dependent manner. Gene silencing of CYP11A1 prevented CD4 Th2 and CD8 Tc2 differentiation. Levels of cortisol were reduced in parallel. The data collected indicate that CYP11A plays an important role in the development of allergy and that the therapeutic approach seen in peanut allergy could be applicable to other allergic diseases.

Potential Applications

Treatment or prevention of allergic diseases by administration of CYP11A1 inhibitors such as aminoglutethimide

State of Development

Investigators are currently screening libraries to identify molecules that will inhibit CYP11A.

Publications

  • Wang et al. (2013) J. Allergy Clin Immunol. 131(2) Supplement: Page AB143

Patent Status

US and International patents pending.

Inventors

Erwin Gelfand, MD, Meiquin Wang, MD, Ph.D. and Yi Jia

Licensing Status

This technology is available for licensing.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback to "Targeting CYP11A1 in the Steroidogenic Pathway for Treating Allergic Diseases"

  

latest entries

latest entries